Literature DB >> 27109056

Aptamers: The "evolution" of SELEX.

Yi Xi Wu1, Young Jik Kwon2.   

Abstract

It has been more than two decades since the first aptamer molecule was discovered. Since then, aptamer molecules have gain much attention in the scientific field. This increasing traction can be attributed to their many desirable traits, such as 1) their potentials to bind a wide range of molecules, 2) their malleability, and 3) their low cost of production. These traits have made aptamer molecules an ideal platform to pursue in the realm of pharmaceuticals and bio-sensors. Despite the broad applications of aptamers, tedious procedure, high resource consumption, and limited nucleobase repertoire have hindered aptamer in application usage. To address these issues, new innovative methodologies, such as automation and single round SELEX, are being developed to improve the outcomes and rates in which aptamers are discovered.
Copyright © 2016 Elsevier Inc. All rights reserved.

Keywords:  Aptamers; SELEX

Mesh:

Substances:

Year:  2016        PMID: 27109056     DOI: 10.1016/j.ymeth.2016.04.020

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  26 in total

Review 1.  Achieving Controlled Biomolecule-Biomaterial Conjugation.

Authors:  Christopher D Spicer; E Thomas Pashuck; Molly M Stevens
Journal:  Chem Rev       Date:  2018-07-24       Impact factor: 60.622

Review 2.  High performance affinity chromatography and related separation methods for the analysis of biological and pharmaceutical agents.

Authors:  Chenhua Zhang; Elliott Rodriguez; Cong Bi; Xiwei Zheng; Doddavenkatana Suresh; Kyungah Suh; Zhao Li; Fawzi Elsebaei; David S Hage
Journal:  Analyst       Date:  2018-01-15       Impact factor: 4.616

Review 3.  Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.

Authors:  Bruktawit Maru; Lea Nadeau; Maureen McKeague
Journal:  ACS Pharmacol Transl Sci       Date:  2021-11-17

4.  Solution structure of a thrombin binding aptamer complex with a non-planar platinum(ii) compound.

Authors:  Bo-Chen Zhu; Juan He; Xiao-Yu Xia; Jingxing Jiang; Wenting Liu; Liu-Yi Liu; Bing-Bing Liang; Hua-Gang Yao; Zhuofeng Ke; Wei Xia; Zong-Wan Mao
Journal:  Chem Sci       Date:  2022-06-23       Impact factor: 9.969

Review 5.  Clinical and pharmaceutical applications of affinity ligands in capillary electrophoresis: A review.

Authors:  Chenhua Zhang; Ashley G Woolfork; Kyungah Suh; Susan Ovbude; Cong Bi; Marawan Elzoeiry; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2019-09-12       Impact factor: 3.935

Review 6.  Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting.

Authors:  Heather H Gustafson; Audrey Olshefsky; Meilyn Sylvestre; Drew L Sellers; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2018-06-28       Impact factor: 15.470

Review 7.  Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.

Authors:  Pascal Röthlisberger; Cécile Gasse; Marcel Hollenstein
Journal:  Int J Mol Sci       Date:  2017-11-16       Impact factor: 5.923

8.  Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa.

Authors:  David A Donkor; Varsha Bhakta; Louise J Eltringham-Smith; Alan R Stafford; Jeffrey I Weitz; William P Sheffield
Journal:  Sci Rep       Date:  2017-05-18       Impact factor: 4.379

9.  Refining the Results of a Classical SELEX Experiment by Expanding the Sequence Data Set of an Aptamer Pool Selected for Protein A.

Authors:  Regina Stoltenburg; Beate Strehlitz
Journal:  Int J Mol Sci       Date:  2018-02-24       Impact factor: 5.923

10.  Improvement of the activity of the anti-HIV-1 integrase aptamer T30175 by introducing a modified thymidine into the loops.

Authors:  Antonella Virgilio; Teresa Amato; Luigi Petraccone; Francesca Esposito; Nicole Grandi; Enzo Tramontano; Raquel Romero; Shozeb Haider; Isabel Gomez-Monterrey; Ettore Novellino; Luciano Mayol; Veronica Esposito; Aldo Galeone
Journal:  Sci Rep       Date:  2018-05-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.